MedTrace Logo

Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)

NCT02953704 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1469

Last updated 2022-05-13

No results posted yet for this study

Summary

The purpose of this prospective, longitudinal, noninterventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofibrosis (MF).

Conditions

  • MPN (Myeloproliferative Neoplasms)

Sponsors & Collaborators

Principal Investigators

  • Robyn M. Scherber, MD, MPH · Incyte Corporation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2022-03-29
Completion
2022-03-29

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02953704 on ClinicalTrials.gov